ImmunityBio Securities Class Action
Follow to receive email when new source reporting is added to this case. Email delivery also depends on your profile notification settings and a verified email address.
ImmunityBio · IBRX securities · Ongoing Litigation
Last updated
Case overview
- Defendant company
- ImmunityBio
- Product or service
- IBRX securities
- Case status
- Ongoing Litigation
- Lawsuit type
- Securities
- Reported harm
- Other
Important dates
- Lead plaintiff application
Participation information
Availability is based on each listed participation option and its deadline.
Lead plaintiff application
Investors who purchased or acquired ImmunityBio securities between January 19, 2026, and March 24, 2026, and suffered investment losses.
Investors could file to be lead plaintiff by May 26, 2026, or retain counsel of choice or take no action.
- Type
- Lead Plaintiff
- Status
- Deadline passed
- Reported proof requirement
- Unclear
This information does not determine whether you qualify for a case.
Sources
Public reporting associated with this case.
- ImmunityBio Securities Class Action
Benzinga ·